Summary
Picotamide (G 137), a new non prostanoid inhibitor of in vitro arachidonic acid induced platelet aggregation, has been further characterized in in vitro and ex vivo studies.
When whole blood was activated with collagen in the presence of picotamide 5×10−4 M, thromboxane B2 production was decreased, and 6-keto-PGF1α generation was significantly increased, suggesting a reorientation of platelet endoperoxide metabolism following blockade of thromboxane synthetase. Picotamide also inhibited platelet aggregation and clot retraction induced by the endoperoxide analogue U46619 in human platelets, indicating thromboxane A2-receptor antagonism, possibly of competitive nature.
A single oral dose of picotamide 1 g in 24 healthy volunteers produced a significant inhibition of collagen, arachidonic acid and U46619-induced platelet aggregation. Serum levels of thromboxane B2 were also reduced.
Chronic administration of picotamide 1.2 g/d to patients with vascular disease resulted in a prompt and persistent fall in their increased plasma levels of β-thromboglobulin.
The results indicate that picotamide is a combined thromboxane B2-synthetase inhibitor and thromboxane A2-receptor antagonist in human platelets, and that it may prove useful as an antithrombotic agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hamberg M, Svensson J, Samuelsson (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994–2998
Ogletree ML (1987) Overview of physiological and pathophysiological effects of thromboxane A2. Federation Proc 46: 133–138
Smith BJ (1987) Pharmacology of thromboxane synthase inhibitors. Federation Proc 46: 139–143
Lefer AM, Darius H (1987) A pharmacological approach to thromboxane receptor antagonism. Federation Proc 46: 144–148
De Cunto M, Berrettini M, Parise P, De Regis M, Orzalesi G, Nenci GG (1983) Antiaggregating activity of 4-OH-isophthalic acid derivatives: an in vitro study. Boll Soc It Biol Sper 59: 302–308
Berrettini M, De Cunto M, Romanelli A, Volpato I, Orzalesi G, Nenci GG (1983) Mechanism of the antiplatelet activity of picotamide (G 137): an in vitro study. Boll Soc It Biol Sper 59: 309–315
Berrettini M, De Cunto M, Parise P, Grasselli S, Nenci GG (1983) picotamide, a derivative of 4-methoxy-isopthalic acid, inhibits thromboxane synthetase and receptors in vitro and in vivo. Thromb Haemost 50: 127 (abstract)
Nenci GG, Berrettini M, Agnelli G, Parise P, Buoncristiani U, Ballatori E (1979) Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function. Nephron 23: 287–293
Nenci GG, Parise P, Capodicasa E, Berrettini M (1983) Platelet malondialdehyde production kinetics after cyclooxygenase block. Haemostasis 13: 53–60
Villa S, Livio M, De Gaetano G (1979) The inhibitory effect of aspirin on platelet and vascular prostaglandins in rats cannot be completely dissociated. Br J Haematol 42: 425–431
Defreyn G, Deckmyn H, Vermylen J (1982) A thromboxane synthase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 26: 389–400
De Gaetano G, Bottecchia D, Vermylen J (1973) Retraction of reptilase-clots in the presence of agents inducing or inhibiting the platelet adhesion-aggregation reaction. Thromb Res 2: 71–84
Mielke CH, Kaneshiro MM, Maher IA (1969) The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34: 204–215
Defreyn G, Machin SJ, Carreras LO, Vergara Dauden M, Chamone DAF, Vermylen J (1981) Familial bleeding tendency with partial thromboxane synthase deficiency: reorientation of cyclic endoperoxide metabolism. Br J Haematol 49: 29–41
Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J (1989) Characterization of N,N'-bis(3-Picolyl)-4-methoxy-isopthalamide (picotamide) as a dual thromboxane synthase/thromboxane A2 receptor antagonist in human platelets. Thromb Haemostas 61: 479–484
Bertele V, Cerletti C, Schieppati A, Di Minno G, De Gaetano G (1981) Inhibition of thromboxane synthase does not necessarily prevent platelet aggregation. Lancet I: 1057–1058 (letter)
Bertele V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, De Gaetano G (1984) Pharmacologic inhibition of thromboxane synthase and platelet aggregation: modulatory role of cyclooxygenase products. Blood 63: 1460–1466
Di Minno G, Bertele V, Bianchi L, Barbieri B, Cerletti C, Dejana E, De Gaetano G, Silver MJ (1981) Effects of an epoxymethano stable analogue of prostaglandin endoperoxides (U46619) on human platelets. Thromb Haemost 45: 103–106
Haslam RJ, Davidson MM, Davies T, Lynham JA, McClenaghan MD (1978) Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucl Res 9: 533–552
Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J (1987) Role of pro- and anti-aggregatory prostaglandins in haemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 80: 1435–1445
De Clerck F, Beetens J, de Chaffoy Courcelles D, Freyne E, Janssen PA (1989) R68070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule. I. Biochemical profile in vitro. Thromb Haemost 61: 35–42
Gresele P, Van Houtte E, Arnout J, Deckmyn H, Vermylen J (1984) Thromboxane synthase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy? Thromb Haemost 52: 364 (letter)
Fitzgerald DJ, Fragetta J, Fitzgerald GA (1988) Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest: 82: 1708–1713
Feldhoff CM, Gresele P, Pieters G, Vermylen J (1988) Acetylsalicylic acid, BM 13.177 and picotamide improve the survival of endotoxin-infused rabbits. Thromb Res 52: 487–492
Di Perri T, Auteri A, Frigerio C, Volpi L, Blandi P (1989) Farmacologia clinica della picotamide: confronto tra livelli ematici, livelli cellulari e attività antiaggregante del farmaco. Atti Cong. Nazionale Evoluzione della Terapia Antiaggregante Piastrinica, Roma 29 Ottobre 1988, Il Pensiero Scientifico Ed., Roma, pp 21–25
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berrettini, M., De Cunto, M., Parise, P. et al. “In vitro” and “ex vivo” effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Eur J Clin Pharmacol 39, 495–500 (1990). https://doi.org/10.1007/BF00280943
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280943